Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
China Medical System Holdings ( (HK:0867) ) has issued an update.
China Medical System Holdings Limited has entered a collaboration with Hunan Mabgeek Biotechnology for the co-development and exclusive commercialization of MG-K10, a long-acting anti-IL-4Rα monoclonal antibody for treating type 2 inflammatory diseases. The agreement grants exclusive rights across several Asian territories, with MG-K10 showing promising results in clinical trials, potentially positioning it as a market leader in the growing field of biologics targeting IL-4Rα, a sector expected to reach significant market size by 2030.
More about China Medical System Holdings
China Medical System Holdings Limited operates in the pharmaceutical industry, focusing on the development and commercialization of innovative drugs. It specializes in monoclonal antibody injections, targeting significant unmet medical needs in inflammatory diseases across various regions including Mainland China and parts of Asia.
YTD Price Performance: -4.84%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.2B
For detailed information about 0867 stock, go to TipRanks’ Stock Analysis page.
